• GLP-1(7-36) and GLP-1(9-36) inhibit glucagon secretion from alpha-cells
Introduction
Glucagon is the body's principal hyperglycemic hormone (Cryer, 2015) . In both type 1 (T1D) and type 2 diabetes (T2D), hyperglycemia results from a combination of insufficient insulin secretion and oversecretion of glucagon (Unger and Orci, 1975) . Whereas the insulin secretion defect has attracted much attention, the dysregulation of glucagon secretion in diabetes remains, by comparison, an understudied area.
The incretin hormone glucagon-like peptide 1 (GLP-1) is secreted by the Lcells of the gut as GLP-1(7-36) which exerts a strong hypoglycemic effect by stimulating insulin secretion in the β-cells (Holst, 2007) . Following its release, GLP-1(7-36) is quickly degraded by dipeptidyl peptidase 4 (DPP-4) to form the metabolite GLP-1(9-36) (Baggio and Drucker, 2007) . We will refer to the two peptides by their full names and reserve the use of 'GLP-1' to describe total GLP-1. Plasma GLP-1 levels range between 10-50 pM of which only <20% is GLP-1(7-36) and the rest exists as GLP-1(9-36) (Orskov et al., 1994) .
GLP-1(7-36) exerts a glucagonostatic effect (i.e. inhibits glucagon secretion in the pancreatic α-cells). Although this effect is thought to account for ~50% of the peptide's hypoglycemic action (Hare et al., 2010) , the cellular mechanisms underlying the glucagonostatic effect are poorly understood compared to the insulinotropic effects, which are fairly well characterized (Gromada et al., 1998) .
Most studies indicate that GLP-1 receptors (encoded by Glp1r) are expressed at very low levels (if at all) in glucagon-secreting α -cells (De Marinis et al., 2010; Nakashima et al., 2018; Ramracheya et al., 2018; Richards et al., 2014) (but see (Zhang et al., 2019) ). It was therefore argued that GLP-1(7-36) exerts its inhibitory effect on glucagon secretion by a paracrine mechanism mediated by factor(s) secreted by the neighboring β -and δ -cells (e.g. insulin and somatostatin, respectively) within the pancreatic islets (Orgaard and Holst, 2017 ). Yet, robustly inhibit glucagon secretion in isolated islets when tested at non-physiological nanomolar levels by mechanisms that cannot be accounted for by paracrine signals (De Marinis et al., 2010; Ramracheya et al., 2018) . We have previously proposed that this effect is mediated by activation of the limited number of GLP-1 receptors present in α -cells and that this, via a small increase in cAMP, results in inhibition of the voltage-gated Ca 2+ channels linked to exocytosis of glucagon-containing secretory granules.
We have now explored the role of the 'classical' GLP-1 receptor in GLP-1induced effects on glucagon release by extending our studies to Glp1r knockout mice (Scrocchi et al., 1996) . The data suggest that activation of GLP-1Rs only mediate part of the glucagonostatic effect of GLP-1 and that GLP-1 also exerts Glp1r-and PKA-independent effects. Here we have also studied the effects of GLP-1(7-36) and its metabolite, GLP-1(9-36) on human islet function, and explored the possible involvement of alternative receptors and the intracellular signaling mechanisms involved.
Results
Dose-dependent inhibition of glucagon secretion by GLP-1(7-36) and GLP-1(9-36).
We measured glucagon secretion in isolated mouse and human pancreatic islets exposed to 1 mM glucose (this glucose concentration represents a strong stimulus of glucagon secretion) and increasing concentrations of GLP-1(7-36) ( Figure 1A-B ). In both mouse and human islets, GLP-1(7-36) produced a concentration-dependent inhibition of glucagon secretion that was maximal at 1-10 pM; high concentrations (0.1-100 nM) of GLP-1(7-36) were less efficacious than picomolar levels. In the remainder of the manuscript, GLP-1(7-36) was therefore tested at 1 or 10 pM.
Pancreatic islets are extensively vascularized and the disruption of blood flow during the islet isolation process may lead to intra-islet accumulation of secreted products to unphysiological levels. In static incubations of mouse islets, the glucagon and insulin concentrations measured at the end of the 1-h incubations averaged 69±5 pM (n=8) and 130±13 pM (n=8), respectively. To ascertain that intra-islet paracrine factors operating under static incubation conditions do not interfere with the responses, we also tested GLP-1(7-36) at 1 pM and 10 nM using the dynamic perfused mouse pancreas paradigm. In these experiments, the pancreas was perfused at the physiological rate (~0.3 ml/min) and in normal direction of vascular flow (51). This methodology has the additional advantage that the islets have not been subjected to any mechanical or enzymatic treatment. When tested at 1 mM glucose, application of 1 pM and 10 nM GLP-1(7-36) inhibited glucagon secretion by 61±8% (n=3) and 40±3.5% (n=3), respectively ( Figure S1A-B ). These results are in good agreement with those obtained in the static incubation setting, thus validating the latter experimental approach.
In both mouse and human islets, the maximum inhibitory effect of GLP-1(7-36) was comparable to that produced by 6 mM glucose (the glucose concentration with the strongest glucagonostatic effect in both mouse and human islets (Walker et al., 2011) . When tested at supraphysiological concentrations (10 nM), augments the inhibitory effect of high glucose on glucagon secretion in both mouse (De Marinis et al., 2010) and human islets (Ramracheya et al., 2018) . However, the effects of physiological concentrations of GLP-1(7-36) (10 pM) and glucose were not additive in isolated human islets ( Figure S1C ), possibly because a low concentration of GLP-1(7-36) exerts a stronger glucagonostatic effect on its own.
Following its release, GLP-1(7-36) is quickly degraded by dipeptidyl peptidase 4 (DPP-4) to form the metabolite GLP-1(9-36) (Baggio and Drucker, 2007) .
In mouse islets, GLP-1(9-36) inhibited glucagon secretion as potently as GLP-1(7-36) ( Figure 1C) ; the greatest inhibitory effect was produced by 10 pM. As was the case with GLP-1(7-36), high concentrations (≥1 nM) of GLP-1(9-36) were less efficacious than low concentrations (1-10 pM). The maximum inhibitory effect of GLP-1(9-36) (80% at 1 pM) in fact exceeded that produced by 6 mM glucose. In human islets, GLP-1(9-36) was also strongly inhibitory and reduced glucagon secretion at 1 mM glucose by 50% when tested at a concentration of 10 pM ( Figure   1D ), similar to that produced by 10 mM glucose (50%).
We excluded the possibility that GLP-1(9-36) inhibits glucagon secretion by a paracrine effect mediated by stimulation of insulin or somatostatin secretion ( Figure   S2A -D).
Collectively, these data therefore suggest that glucagon secretion is under strong tonic inhibition by circulating levels of GLP-1 (10-50 pM) and that these effects are mediated by direct effects on the α -cells.
Glucagonostatic and insulinotropic effects of GLP-1 are mediated by pharmacologically distinct mechanisms.
The insulinotropic effects of GLP-1(7-36) are shared with the GLP-1 receptor agonist exendin-4, which shows only 53% homology to GLP-1(7-36) (Underwood et al., 2010) . Exendin-4 (10 pM) potentiated glucose (6 mM)-induced insulin secretion by 100% in mouse and human islets (Figure 2A-B ), comparable to that previously observed for GLP-1(7-36) (Shigeto et al., 2015) . By contrast, exendin-4 (0.1 pM-100 nM) was without glucagonostatic effects in mouse islets ( Figure 2C ). Due to limited access, in human islets only a single concentration of exendin-4 (10 pM) was tested on glucagon secretion but the same negative result was observed ( Figure 2D ).
GLP-1(7-36) and GLP-1(9-36) signal by PKA-dependent and -independent mechanisms, respectively.
We compared the glucagonostatic effects of physiological concentrations of GLP-1(7-36) and GLP-1(9-36) in the absence and presence of the PKA-inhibitor 8-Br-Rp-cAMPS. Under control conditions, GLP-1(7-36) (10 pM) inhibited glucagon secretion by 48%, which was reduced to 25% in the presence of 8-Br-Rp-cAMPS (10 µM; p<0.01). By contrast, the effect of GLP-1(9-36) (10 pM) was not at all affected by the PKA inhibitor. In this experimental series, the inhibitory effect of GLP-1(9-36) averaged 42% and 40% (p=0.7) in the absence and presence of 8-Br-Rp-cAMPS, respectively ( Figure 3B ). Thus, it appears that whereas the inhibitory effects of GLP-1(7-36) are partially PKA-dependent, those of GLP-1(9-36) are entirely PKAindependent. Notably, the PKA inhibitor had no effect on glucagon secretion at 1 mM glucose. This argues that cAMP-dependent activation of PKA does not account for the stimulation of glucagon secretion at low glucose, at variance with a recent suggestion (Yu et al., 2019) .
GLP-1(9-36), but not GLP-1(7-36), signals via a G i -dependent mechanism.
We hypothesized that the PKA-independent effects of GLP-1(9-36) are mediated by activation of an inhibitory GTP-binding protein (G i ). We next compared the effects of GLP-1(7-36) and (9-36) in islets pretreated with pertussis toxin (PTX) to inhibit G i (Asano et al., 1984) . Under control conditions (without PTX pre-treatment), GLP-1(7-36) and (9-36) (both tested at 10 pM) inhibited glucagon secretion by >50%.
Following pre-treatment with PTX (100 ng/ml for >4h), the inhibitory effect of GLP-1(9-36) was abolished whereas that of GLP-1(7-36) was unaffected ( Figure 3C) .
These experiments were not repeated in islets from human donors because pretreatment of human islets with PTX exerts a paradoxical strong glucagonostatic effect on its own (Walker et al., 2011) .
The glucagonostatic effect of GLP-1 is retained in Glp1r -/islets.
Collectively, the data presented in Figures 1-3 suggest that GLP-1(7-36) stimulates insulin secretion and inhibits glucagon release by pharmacologically distinct mechanisms that involve separate signal transduction pathways. These findings raise the interesting possibility that the glucagonostatic effects of GLP-1(7-36) and (9-36) involve a receptor distinct from the previously characterized GLP-1 receptor (GLP-1R). We explored this possibility by comparing the effects of GLP-1(7-36) and GLP-1(9-36) on insulin and glucagon secretion in islets isolated from control (Glp1r +/+ ) and GLP-1 receptor knockout (Glp1r -/-) mice.
In wild-type islets, increasing glucose from 1 to 6 mM stimulated insulin secretion by 1.9-fold. Treatment with GLP-1(7-36) (10 pM) resulted in an additional 1.4-fold increase of insulin secretion. In Glp1r -/islets, increasing glucose from 1 to 6 mM also stimulated insulin secretion by 125% but GLP-1(7-36) (10 pM) did not lead to any further stimulation ( Figure 4A ).
The effects of GLP-1(7-36) on glucagon secretion were tested at 1 mM glucose. In control islets, GLP-1(7-36) (10 pM) inhibited glucagon secretion by ~50%.
The inhibitory effects of GLP-1(7-36) persisted in Glp1r -/islets where it amounted to a 55% reduction in glucagon release ( Figure 4B ). Similarly, GLP-1(9-36) (10 pM) was equally inhibitory in Glp1r -/and control islets, suppressing glucagon secretion by ~60% ( Figure 4C ). The inhibitory effects of both, GLP-1(7-36) and GLP-1(9-36) on glucagon secretion were comparable to the suppression resulting from increasing the glucose concentration from 1 to 6 mM. The reduction of glucagon secretion at high glucose concentration was not affected by ablation of Glp1r ( Figure 4B -C).
We point out that the mouse model used for these experiments is a general knockout and the possibility that GLP-1 exerts its inhibitory action by a paracrine effect by activation of GLP-1Rs in δand β -cells can therefore be excluded. Thus, whereas the insulinotropic effect of GLP-1 is mediated by the previously characterized (cloned) GLP-1R, the glucagonostatic effects are probably mediated by activation of different receptor(s).
We next tested the capacity of GLP-1(7-36) to suppress glucagon secretion in islets from Glp1r -/mice following inactivation of G i . In keeping with the data in Figure   4B , GLP-1(7-36) retained its capacity to inhibit glucagon secretion in Glp1r-deficient islets. However, unlike what was observed in control (wild-type) islets, GLP-1(7-36) did not inhibit glucagon secretion in PTX-pretreated Glp1r -/islets ( Figure 4D ).
The latter finding raises the interesting possibility that the Glp1r-independent inhibitory effects of GLP-1(7-36) on glucagon secretion are actually mediated by its breakdown product GLP-1(9-36). DPP-4, the enzyme catalyzing this reaction, is expressed and functionally-active in isolated pancreatic islets (Guida et al., 2017) . To explore this hypothesis, we tested the effects of GLP-1(7-36) (10 pM) in the presence of the DPP-4 inhibitor sitagliptin (100 nM) (Deacon, 2018) and compared the effects on glucagon secretion in the absence or presence of the GLP-1 receptor antagonist exendin(9-39) (100 nM) ( Figure 4E -F). Consistent with the data in Glp1r-deficient islets ( Figure 4B ), GLP-1(7-36) retained an inhibitory effect on glucagon release in the presence of exendin(9-39). However, co-application of sitagliptin and exendin(9-39) abolished the inhibitory effect of GLP-1(7-36) ( Figure 4F ). Importantly, sitagliptin was without stimulatory effect on glucagon secretion when tested in the absence of exendin(9-39) ( Figure 4E ).
GLP-1(9-36) activates the glucagon receptor.
We compared expression of Glp1r and other receptors that can influence glucagon secretion. Consistent with previous reports (De Marinis et al., 2010) , expression of Glp1r and Gcgr in mouse α-cells is lower than that in β-cells. Notably, Glp1r, Gipr and Gpr119 are all expressed in α-cells at levels comparable to Adrb1 (the β 1adrenergic receptor) ( Figure S3A GPR119 were expressed at >10-to 100-fold higher levels ( Figure S3C -D). Notably, both ADRB1 and GPR119 are expressed at much higher levels in α-cells than in β-
cells.
We speculated that the Glp1r-independent effects of GLP-1(7-36) and GLP-1(9-36) might be mediated by activation of the GCGR. In HEK 293 cells expressing human GCGR, glucagon increased cAMP production with an EC 50 of ~1 nM, an effect that was antagonized by the glucagon receptor antagonist L-168049 (Cascieri et al., 1999) ( Figure 5A ). Intriguingly, GLP-1(9-36) also activated the glucagon receptor and increased cAMP content with an EC 50 of 30 nM ( Figure 5B ). This effect was also antagonized by L-168049, confirming that the action is due to activation of the glucagon receptor ( Figure 5B ). While the potency is relatively low in these cells, this is probably due to the insensitive nature of the cAMP reporter assay used.
Receptor activity-modifying proteins (RAMPs) modulate the pharmacology of G protein-coupled receptors (McLatchie et al., 1998) . In human islets, RAMP2 is expressed at much higher (~20-fold) levels in the α -than in β -cells (Blodgett et al., 2015) ( Figure S3B ). Whereas the capacity of GLP-1(7-36) to activate the human GCGR is abolished when the receptor is co-expressed with RAMP2 (Weston et al.,
2015)
, the activating potency of GLP-1(9-36) was enhanced 30-fold; the EC 50 was reduced from 10 nM to 0.3 nM ( Figure 5C ). Significantly, and in contrast to both GLP-1(7-36) and (9-36), exendin-4 was without effect on cAMP production in GCGRexpressing HEK 293 cells ( Figure 5D ).
Given the high expression of Gpr119/GPR119 in mouse and human α-cells,
we explored the possibility that activation of this receptor may contribute to GLP-1's glucagonostatic effects. The Gpr119 agonist AS1269574 inhibited glucagon secretion in isolated mouse islets when applied at concentrations of 0.3-3 nM but was ineffective at higher concentrations ( Figure S4A ). However, both GLP-1(7-36) and (9-36) remained capable of inhibiting glucagon secretion in islets from Gpr119 -/mice ( Figure S4B -C) and neither GLP-(7-36) nor (9-36) activated GPR119 expressed in HEK 293 cells even when tested at concentrations as high as 10 μM ( Figure S4D ).
We finally excluded the possibility that the GLP-1R agonists mediate their actions through the activation of GIPRs ( Figure S5 ).
Loss of glucagonostatic effect of GLP-1(7-36) and (9-36) in Gcgr -/islets. The receptor activation studies raise the interesting possibility that GLP-1(9-36) may act by activating the glucagon receptors. GCGR is pleiotropically coupled, i.e. activating not only stimulatory G s but also the inhibitory G i GTP-binding proteins (Weston et al., 2015; Weston et al., 2014; Wootten et al., 2016) . In HEK 293 cells expressing the GCGR, pretreatment with pertussis toxin increased cAMP accumulation in response to GLP-1(9-36) ( Figure S6 ), indicating that GLP-1(9-36) can activate G i . It was ascertained that there was no increase in cAMP in HEK 293 cells not expressing GCGR.
The studies with recombinant glucagon receptors and glucagon receptor antagonists suggest that GLP-1(9-36) may activate glucagon receptors (GCGRs).
We therefore compared the effects of GLP-1(7-36) (10 pM) and (9-36) (10 pM) in islets from control and Gcgr -/mice (Gelling et al., 2003) . In wildtype islets, GLP-1(7-36) and GLP-1(9-36) applied at 1 mM glucose inhibited glucagon secretion as strongly as increasing glucose from 1 to 6 mM ( Figure 6A ).
Consistent with earlier reports (Gelling et al., 2003) , Gcgr -/mice exhibited marked α-cell hyperplasia with the glucagon content being ~10-fold higher than in wildtype islets and rate of glucagon release correspondingly increased ( Figure 6C ).
For display purposes glucagon secretion in Gcgr -/islets was normalized to that at 1 mM glucose. Unlike what was observed in wildtype islets, neither GLP-1(7-36), nor GLP-1(9-36) exerted any statistically significant glucagonostatic effects in Gcgr -/islets ( Figure 6B ). It should be noted that that these islets likewise failed to respond to elevated glucose with suppression of glucagon secretion, suggesting that the function of α-cell in Gcgr -/mice may extend beyond the permanent loss of glucagon signaling. Notably, ablation of GCGR did not affect glucagon secretion at 1 mM glucose and in both wild-type and Gcgr -/islets the fractional rate of release was ~0.1%/h ( Figure 6D ).
Glucagon receptor antagonists abolish glucagonostatic effect of GLP-1(9-36).
To avoid long-term/compensatory effects of genetically ablating the GCGRs, we compared the glucagonostatic effects of physiological concentrations of in mouse islets in the absence and presence of the glucagon receptor antagonist L-168049 (Cascieri et al., 1999) .
Under control conditions, GLP-1(9-36) (10 pM) inhibited glucagon secretion in mouse islets by ~50% ( Figure 6E ). When tested in the presence of L-168049, GLP-1(9-36) failed to affect glucagon secretion. In the same islets, elevation of glucose to 6 mM inhibited glucagon secretion ~50% (confirming that the α -cells were functional).
These experiments were repeated in human islets. We observed that GLP-(9-36) (10 pM) inhibited glucagon secretion in human islets almost as strongly as 6 mM glucose (48% and 56%, respectively) and that the effect of the GLP-1 metabolite was abolished by the glucagon receptor antagonists desHis 1 Pro 4 Glu 9 glucagon ("Peptide N) and desHis 1 Pro 4 Glu 9 Lys 12 FA-glucagon ('Peptide R) (O'Harte et al., 2014) ( Figure   6F ).
In both mouse and human islets, glucagon secretion at 1 mM glucose was not affected by inclusion of the glucagon receptor antagonists in the incubation media. Taken together with the observation in Gcgr -/islets it can be concluded that glucagon is not a feedback regulator of its own release.
Effects of GLP-1(9-36) in vivo.
Plasma glucose reflects the balance between the hypoglycemic action of insulin and hyperglycemic action of glucagon. The observation that GLP-1(9-36) inhibits glucagon secretion in vitro therefore suggests that it may affect systemic glucose homeostasis. GLP-1(9-36) was administered intraperitoneally in mice at a dose of 500 ng/g body weight as reported previously by other investigators (Day et al., 2017) .
Plasma GLP-1(9-36) peaked after 10 min, attaining a maximal concentration of 400 pM. The concentration then decayed exponentially but remained >60 pM (5-fold higher than basal) 60 min after injection of the peptide ( Figure S7A ), close to that producing the maximum glucagonostatic effect in the in vitro measurements (cf. Figure 1C ) but it was without effect on plasma glucose and glucagon when administered to fed mice with a plasma glucose of 11±0.5 mM (n=7) ( Figure S7B -C).
We reasoned that the systemic effects of GLP-1(9-36) might be more apparent when glucagon secretion is stimulated by insulin-induced hypoglycaemia.
In mice fasted for 5h, insulin (0.5 U/kg body weight) lowered plasma glucose from a basal 7.5 mM to 4 mM ( Figure 7A ). This was associated with a ~10-fold increase in plasma glucagon at 30 and 45 min after induction of hypoglycemia ( Figure 7B ).
When insulin was co-injected with GLP-1(9-36), plasma glucose followed the same trajectory as when insulin was administered alone ( Figure 7A ) but the stimulation of glucagon secretion was reduced by ~40% ( Figure 7B ). This inhibition is similar to that observed in isolated islets ( Figure 1C -D). Following more extended fasting, a stronger hypoglycemic effect of GLP-1(9-36) was observed ( Figure S7D -F).
Discussion
Here we have studied the effects of GLP-1(7-36) and its metabolite, GLP-1(9-36) on pancreatic islet function. We propose that GLP-1(7-36) and GLP-1(9-36) inhibit glucagon secretion by a combination of (at least) two mechanisms that involve distinct receptors and intracellular signal transduction pathways. Whereas one of these is mediated by binding of GLP-1(7-36) to the cloned GLP-1R, the second mechanism is mediated by the degradation product GLP-1(9-36), involves binding to the glucagon receptor (GCGR) and culminates in activation of a pertussis toxinsensitive inhibitory GTP-binding protein.
Whereas the two mechanisms normally cooperate, they may (under certain experimental conditions) individually suffice to maximally suppress glucagon secretion. Accordingly, genetic ablation of one receptor subtype may not be enough to produce a clear phenotype and combination of genetic and pharmacological strategies are therefore required to unveil the role of the different receptors. We emphasize that our findings are fully consistent with the previously proposed concept GLP-1 signaling in α-cells. Plasma GLP-1 levels range between 10-50 pM of which only <20% is GLP-1(7-36) (Holst, 2007) . In isolated islets, glucagon secretion was strongly inhibited by GLP-1(7-36) and (9-36) at concentrations as low as 1-10 pM ( Figure 1 ). Accordingly, glucagon secretion is under strong tonic inhibition by circulating levels of GLP-1(7-36) and GLP-1(9-36). This may explain the observation that cell-specific ablation of Glp1r in α -cells leads to increased plasma glucagon in fed mice (Zhang et al., 2019) .
The physiological role of the glucagonostatic effect of GLP-1(9-36) remains to be established but it may serve to restrict glucagon secretion following a mixed meal, for example, the increase in circulating amino acids would otherwise lead to strong stimulation of glucagon secretion, which would be functionally inappropriate.
Whether Glp1r is present in glucagon-secreting α -cell remains debated but most studies agree that it is expressed at much lower levels than in the neighboring β -cells (Blodgett et al., 2015; DiGruccio et al., 2016; Richards et al., 2014) . In this study, expression of Glp1r in α-cells was only ~2% of the non-α-cells (i.e. βand δcells) ( Figure S3 ). As expected, genetic ablation of Glp1r abolished the potentiating effect of GLP-1 on glucose-induced insulin secretion. However, the glucagonostatic effects of both GLP-1(7-36) and (9-36) were unaffected.
GLP-1R-and PKA-dependent effects of GLP-1 in α-cells
Despite the low expression of Glp1r in α-cells and the finding that the glucagonostatic effect of GLP-1 was seemingly intact in Glp1r -/mice, it nevertheless appears that these receptors contribute to the glucagonostatic action of GLP-1(7-36). This is suggested by observations made with/without pretreatment with pertussis toxin (PTX). In wild-type islets, the glucagonostatic effect of GLP-1(7-36) is unaffected by pretreatment with PTX. In Glp1r -/mice, GLP-1(7-36) was still inhibitory under control conditions but failed to suppress glucagon secretion after PTX pretreatment.
How GLP-1(7-36) exerts its glucagonostatic effect remains unclear but we have previously proposed that activation of the few receptors present on the α-cells leads to a small increase in intracellular cAMP, sufficient to activate PKA with resultant inhibition of glucagon secretion (De Marinis et al., 2010) . This also explains our present finding that the PKA-inhibitor 8-Br-Rp-cAMPS reduces the inhibitory effect of GLP-1(7-36) by 50% ( Figure 3A) . The downstream PKA-dependent mechanism leading to inhibition of glucagon secretion remains to be identified but there is evidence that the effect is mediated by inhibition of high voltage-activated P/Q-type Ca 2+ channels sensitive to ω-agatoxin (Ramracheya et al., 2018) ( Figure   S8 ). This scenario is supported by the findings that low concentrations of the adenylate cyclase activator forskolin as well as adrenaline inhibit rather than stimulate glucagon secretion and it is only at high concentrations of the compounds that stimulation of glucagon secretion is observed (De Marinis et al., 2010) . The latter effect may contribute to the observed paradox that high (nM) concentrations of GLP-1 are less inhibitory on glucagon release than low (pM) concentrations of the hormone; this may be because high concentrations of GLP-1(7-36) increase intracellular cAMP slightly more than required to produce maximal inhibition of glucagon release. We also considered the possibility that the weaker inhibitory effect may reflect GLP-1R receptor desensitization (35) but it is notable that 1 pM GLP-1(7-36) remained strongly inhibitory when applied after a 2-min exposure to 10 nM of the incretin; if receptor desensitization had occurred, then its inhibitory effect should have been reduced compared to when the low concentration was applied to begin with. Receptor binding studies using the cloned human GCGR suggest that they are activated by GLP-1(9-36) and that this culminates in activation of G i . Indeed, GCGR antagonists prevent the glucagonostatic effect of GLP-1(9-36). The suppression of glucagon secretion produced by GLP-1(9-36), but not that by GLP-1(7-36), was prevented in islets pretreated with pertussis toxin. Activation of GCGR by GLP-1(9-36) was enhanced by RAMP2, which is expressed at much higher levels possible that GLP-1(9-36) may have the same effect. We acknowledge that expression of Gcgr is low in α-cells but a role of glucagon receptors is supported by the finding that GLP-1 had no statistically significant glucagonostatic effect in Gcgr -/islets.
Pertussis toxin-sensitive and GLP-1R-independent effects of GLP
It would appear counterintuitive that picomolar concentrations of GLP-1(9-36) inhibit glucagon secretion by activation of GCGRs and yet high endogenous glucagon (>30 nM; (Svendsen et al., 2018)) does not exert any glucagonostatic effects. One potential explanation could be that the kinetic rates for the binding of the agonists to the receptor differ. It is at least theoretically possible that when GLP-1(9-36) binds to the GCGR, it has a slow off rate resulting in prolonged signalling effects compared to glucagon. A second alternative could relate to the extent of agonistinduced internalisation of the receptors. While glucagon may induce rapid GCGR internalisation, GLP-1(9-36) may not, resulting in a sustained and prolonged response. We acknowledge that the EC 50 for the stimulation of cAMP production in the receptor binding studies are >100-fold higher than the EC 50 for the glucagonostatic effects observed in the secretion studies. However, it is possible that there is a strong 'amplification' of the response and that the downstream effector mechanisms saturate even when receptor activation is submaximal.
Coda: Beyond the α -cell. These findings suggest that GLP-1 exerts, at least part of, its effects on glucagon secretion by a Glp1r-independent mechanism as also suggested for its cardioprotective effects in the rodent heart (Ban et al., 2010). There have been multiple reports that GLP-1(7-36) and GLP-1(9-36) exert effects on the CNS (Table S1 ). Islets were isolated as previously described (Ramracheya et al., 2010) . Human islets were usually released for experimental work within 24h of islet isolation. During the interval between islet isolation and the hormone secretion studies, islets were maintained in complete RPMI medium containing 5 mM glucose for up to 2 days prior to the experiments.
Animals, islet isolation and whole pancreas perfusion. Most studies were conducted in 8-16 weeks old mice on a C57BL6/J or NMRI background. For experiments with the mouse knockout models, sex-and age-matched wild type littermates were used as controls. 0
The mice were killed by cervical dislocation, the pancreas quickly resected and pancreatic islets isolated by liberase (Sigma) digestion. The islets were handpicked, size-matched and grouped manually.
Reagents. GLP-1(7-36), GLP-1(9-36), exendin-4 and exendin(9-39) were Measurements of islet hormone secretion. Mouse islets were used acutely, except for studies with PTX, where islets were treated with the toxin for at least 4 hours, and were, pending the experiments, maintained in tissue culture for <24 h in RPMI medium containing 10% fetal bovine serum (FBS), 1% penicillin/streptomycin 1 and 10 mM glucose prior to the measurements. Human islets were maintained in culture for up to 48 h in RPMI medium containing 10% fetal bovine serum (FBS), 1% penicillin/streptomycin and 5 mM glucose.
Experiments were conducted using batches of 10-15 size-matched islets per tube (in triplicate) as previously described (Ramracheya et al., 2010; Vergari et al., 2019) . We note that glucagon secretion exhibits variability between preparations. To circumvent these confounds, each donor/group of mice were used as its own control when testing the effect of a compound.
Islets were washed twice in RPMI prior to preincubation in Krebs-Ringer buffer (KRB) containing 2 mg/ml BSA (S6003, Sigma-Aldrich) and 3 mM glucose for 1 h at 37 o C. Following this, islets were incubated in 0.3 ml KRB with 2 mg/ml BSA, supplemented with various glucose concentrations or compounds as indicated. After incubation, the supernatant was removed and quickly frozen and stored at −80°C.
The islet pellets were lysed with 0.1 ml ice-cold acid ethanol. Insulin and glucagon were determined by radioimmunoassay (Millipore and Oxford Biosystem, respectively) according to the manufacturers' instructions. The concentration of glucagon secreted by the islets ranged between ~1.5-7.5 pg/islet/h (~100-450 pg/ml) for mouse islets and between ~2-10 pg/islet/h (~140-590 pg/ml) for human islets.
Whole pancreas perfusion studies were done as described previously (51).
Receptor binding studies. Plasma glucose measurements during insulin tolerance tests. Fed blood glucose levels (data point before fasting) were measured from a blood drop obtained by a tail vein nick using the Accu-Chek Aviva kit (Roche Diagnostic). The mice were then fasted for 5h prior to the experiments. Fast-acting human insulin (Actrapid, Novo Nordisk) was injected intraperitoneally at the indicated doses with a 25-gauge needle at time zero. GLP-1(9-36) was injected intraperitoneally with insulin as indicated. In the control experiments, insulin was co-injected with the solvent.
Tail vein blood glucose and glucagon levels were monitored using a glucometer before and an ELISA (Mercodia Glucagon ELISA, Uppsala, Sweden).
Total GLP-1 was measured by ELISA (Crystal Chem, Zaandam, Netherlands).
Statistics. All data are reported as mean ± SEM, unless otherwise stated. 
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Figure legends
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